NeuroMetrix Reports DPNCheck® Expansion in China
July 09 2020 - 1:00PM
NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded
distribution in China for DPNCheck, a fast, accurate and
quantitative nerve conduction test for evaluation of peripheral
neuropathies such as diabetic peripheral neuropathy (DPN).
DPNCheck was launched in China in 2016 by Omron
Medical (Beijing) Ltd. (“Omron”), the Company’s exclusive China
distributor. In addition to DPNCheck, Omron markets a wide range of
medical products with a particular focus on diabetes and metabolic
issues. Omron has been a leader in the establishment of
comprehensive metabolic testing centers in hospitals with a large
diabetes population. Currently there are over 300 China hospitals
offering an Omron-designed Metabolic Management Center (MMC) which
encompasses DPNCheck testing.
Omron recently entered a collaboration with
Yabao Pharmaceutical Co., Ltd (“Yabao”) for marketing DPNCheck
initially in north China, Shanxi Provence, and potentially in a
broader territory. Yabao is a top 100 Chinese pharmaceutical
company, listed on the Shanghai exchange, with annual revenues of
about $425M and a sales force of about 3,000 employees. It is
focused on chronic diseases affecting the elderly, women, and
children, including those with diabetes. Omron and Yabao will
address the opportunity in north China to improve patient care for
diabetic neuropathy involving DPNCheck and Yabao pharmaceutical
products.
“Omron Medical is pleased to join with Yabao in
bringing improved care to patients with health complications from
diabetes,” said Mr. Yao Zhao, CEO of Omron Healthcare China.
“DPNCheck plays an important diagnostic role in diabetic
neuropathy, thereby facilitating more effective patient treatment
with Yabao pharmaceutical products.”
About DPNCheck
DPNCheck is a fast, accurate, and quantitative
nerve conduction test that is used to evaluate peripheral
neuropathies such as diabetic peripheral neuropathy (DPN). It is
designed to be used by clinicians at the point-of-care to
objectively detect, stage, and monitor DPN. More information is
available at www.dpncheck.com.
About NeuroMetrix
NeuroMetrix is a leading developer and
manufacturer of diagnostic and therapeutic neurostimulation-based
medical devices that are used throughout the world. The
Company has three FDA cleared commercial products.
DPNCheck® is a point-of-care test that is used to evaluate
peripheral neuropathies. ADVANCE™ is a point-of-care device
that provides nerve conduction studies as an aid in diagnosing and
evaluating patients suspected of having focal or systemic
neuropathies. Quell® 2.0 is a wearable, mobile app
enabled, neurostimulation device indicated for symptomatic relief
and management of chronic pain and is available
over-the-counter. For more information, visit
NeuroMetrix.com.
NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief
Financial Officer neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2023 to Apr 2024